DE841940T1 - Isolierung und/oder konservierung von dentritischen zellenfür die immuntherapie von prostatakrebs - Google Patents

Isolierung und/oder konservierung von dentritischen zellenfür die immuntherapie von prostatakrebs

Info

Publication number
DE841940T1
DE841940T1 DE0841940T DE96927268T DE841940T1 DE 841940 T1 DE841940 T1 DE 841940T1 DE 0841940 T DE0841940 T DE 0841940T DE 96927268 T DE96927268 T DE 96927268T DE 841940 T1 DE841940 T1 DE 841940T1
Authority
DE
Germany
Prior art keywords
seq
prostate cancer
cells
use according
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0841940T
Other languages
German (de)
English (en)
Inventor
Alton Boynton
Gerald Murphy
Benjamin Tjoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwest Biotherapeutics LLC
Original Assignee
Northwest Biotherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics LLC filed Critical Northwest Biotherapeutics LLC
Publication of DE841940T1 publication Critical patent/DE841940T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE0841940T 1995-07-31 1996-07-29 Isolierung und/oder konservierung von dentritischen zellenfür die immuntherapie von prostatakrebs Pending DE841940T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/509,254 US5788963A (en) 1995-07-31 1995-07-31 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
PCT/US1996/012389 WO1997004802A1 (en) 1995-07-31 1996-07-29 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy

Publications (1)

Publication Number Publication Date
DE841940T1 true DE841940T1 (de) 2001-08-23

Family

ID=24025874

Family Applications (1)

Application Number Title Priority Date Filing Date
DE0841940T Pending DE841940T1 (de) 1995-07-31 1996-07-29 Isolierung und/oder konservierung von dentritischen zellenfür die immuntherapie von prostatakrebs

Country Status (9)

Country Link
US (2) US5788963A (enExample)
EP (2) EP2377548A3 (enExample)
JP (1) JP4267692B2 (enExample)
AU (1) AU723607B2 (enExample)
CA (1) CA2228176C (enExample)
DE (1) DE841940T1 (enExample)
IL (1) IL123079A0 (enExample)
NZ (1) NZ315441A (enExample)
WO (1) WO1997004802A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US20040110283A1 (en) * 1997-02-27 2004-06-10 University Of Pittsburgh Of The Commonwealth System Of Higher Education Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6340569B1 (en) 1997-11-12 2002-01-22 University Of Pittsburgh Monoclonal antibody and antigens specific therefor and methods of using same
WO1999043710A1 (en) * 1998-02-26 1999-09-02 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
WO1999046984A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions and methods for the frozen storage of dendritic cells
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
WO1999058678A2 (en) * 1998-05-11 1999-11-18 Micromet Gmbh Antibodies to dendritic cells and human dendritic cell populations and uses thereof
US7351546B2 (en) * 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
DE69942100D1 (de) 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
CA2760534A1 (en) 1999-04-14 2000-10-19 Novartis Vaccines And Diagnostics, Inc. Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
AU785198B2 (en) * 1999-11-15 2006-11-02 Miltenyi Biotec B.V. & Co. KG Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2001039594A2 (en) * 1999-12-03 2001-06-07 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2001242190A1 (en) * 2000-03-31 2001-10-15 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
AU6778001A (en) 2000-05-11 2001-11-20 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
EP2363139B1 (en) * 2000-05-12 2016-03-02 NorthWest Biotherapeutics, Inc. Method to increase class I presentation of exogenous antigens by human dendritic cells
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20020150588A1 (en) * 2000-09-21 2002-10-17 Allison James P. SPAS-1 cancer antigen
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CA2448599A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells
ES2766299T3 (es) 2001-09-06 2020-06-12 Northwest Biotherapeutics Inc Composiciones y procedimientos para la activación linfocitaria de células dendríticas monocíticas y células T para generar una respuesta Th-1
EP1435776A4 (en) 2001-09-24 2006-01-25 Univ Pittsburgh VACCINE AGAINST CANCER AND DIAGNOSTIC PROCEDURE AND REAGENTS
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
ES2369077T3 (es) * 2002-06-06 2011-11-25 Immunicum Ab Nuevo procedimiento y composición para producir una vacuna alogénica celular.
ES2755552T3 (es) * 2002-06-19 2020-04-22 Northwest Biotherapeutics Inc Dispositivos de filtración de flujo tangencial y métodos para el enriquecimiento de leucocitos
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
BRPI0317064B8 (pt) * 2002-12-06 2021-05-25 Northwest Biotherapeutics Inc composições compreendendo células dendríticas parcialmente amadurecidas in vitro
WO2004066947A2 (en) * 2003-01-28 2004-08-12 Shanghai Sunway Biotech Co., Ltd. Hyperthermia oncolysis co-therapy
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
AU2004214896A1 (en) 2003-02-27 2004-09-10 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
WO2005037995A2 (en) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
WO2005043155A1 (en) * 2003-10-21 2005-05-12 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
US8153426B2 (en) 2004-08-19 2012-04-10 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma-delta T cells and use in immunotherapy
US8435507B2 (en) * 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
EP1888105A2 (en) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
KR20220113543A (ko) * 2005-12-08 2022-08-12 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008127285A2 (en) * 2006-10-05 2008-10-23 The Board Of Trustees Of The University Of Arkansas Target peptides for ovarian cancer immunotherapy
DK2234642T3 (en) 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
DK2328923T3 (en) 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
PT2326350E (pt) 2008-09-08 2013-12-10 Psma Dev Company L L C Compostos para matar células cancerosas resistentes a taxano, que expressam psma
ES2394180T3 (es) 2008-11-24 2013-01-23 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Receptor de células T de alta afinidad y uso del mismo
PL2427485T3 (pl) * 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
EP2429585B1 (en) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Vaccine immunotherapy
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US20110251128A1 (en) * 2010-02-26 2011-10-13 The Board Of Regents Of The University Of Texas System THYMOSIN Beta4 PEPTIDES PROMOTE TISSUE REGENERATION
US9629357B2 (en) * 2013-02-01 2017-04-25 Primegen Biotech Llc Cryopreservation of cells and tissue for clinical application
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US10320290B2 (en) * 2013-08-09 2019-06-11 Microsemi Corporation Voltage regulator with switching and low dropout modes
DK3277325T3 (da) 2015-04-03 2021-01-18 H Lee Moffitt Cancer Ct & Res Kombinationsimmunterapi for cancer
EP3291821A4 (en) 2015-05-07 2019-03-20 Baylor College of Medicine IMMUNOTHERAPY WITH DENDRITIC CELLS
SG11201804197RA (en) 2015-11-18 2018-06-28 Orbis Health Solutions Llc T7 alpha viral vector system
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
WO2017181163A2 (en) 2016-04-16 2017-10-19 Oncocyte Corporation Methods and compositions for detection and diagnosis of breast cancer
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
EP0692973A1 (en) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
CA2192655A1 (en) * 1994-06-14 1995-12-21 Edgar G. Engleman Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Also Published As

Publication number Publication date
CA2228176C (en) 2015-05-26
JP2001520633A (ja) 2001-10-30
EP2377548A2 (en) 2011-10-19
CA2228176A1 (en) 1997-02-13
US5788963A (en) 1998-08-04
AU6714696A (en) 1997-02-26
JP4267692B2 (ja) 2009-05-27
EP2377548A3 (en) 2012-10-10
MX9800821A (es) 1998-10-31
NZ315441A (en) 1999-06-29
AU723607B2 (en) 2000-08-31
US20130017600A1 (en) 2013-01-17
WO1997004802A1 (en) 1997-02-13
IL123079A0 (en) 1998-09-24
EP0841940A1 (en) 1998-05-20
EP0841940A4 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
DE841940T1 (de) Isolierung und/oder konservierung von dentritischen zellenfür die immuntherapie von prostatakrebs
DE69334186T2 (de) Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen
DE69929533T2 (de) Immunotherapeutische methoden mit verwendung von wt-1 and gata-1 epitopen
DE69937294T2 (de) Von cyclophilin b abstammende tumorantigen-peptide
DE69520959T2 (de) Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung
DE102004026135A1 (de) An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE60133287T2 (de) Tumorantigen
Nakata et al. Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo.
KR100863853B1 (ko) 더블유티1 개변 펩티드
DE69519748T2 (de) Aus den vorstufen des mage tumor-abstossungsantigen abstammende einzelne peptede, die hla-a2 moleküle komplexieren
EP1507795A1 (de) An mhc-moleküle bindende tumor-assoziierte peptide
Lee et al. Heterogeneity of human γδ T cells and their role in cancer immunity
DE60208692T2 (de) Interleukin -18 mutantenproteine, deren herstellung und verwendung
Mosier et al. Cellular deficit in thymectomized mice
DE102005041616B4 (de) Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
Boesteanu et al. Distinct roles for signals relayed through the common cytokine receptor γ chain and interleukin 7 receptor α chain in natural T cell development
ATE17858T1 (de) Angiotropine aus leukozyten und entzuendeten geweben: eine neue klasse von natuerlichen chemotropischen und mitogenen proteinen fuer die spezifische induktion des gesteuerten wachstums von blutgefaessen, fuer neue gefaessbildung von geweben und fuer die morphogenese von blutgefaessverzweigungen; verfahren zu ihrer biotechnischen herstellung und pharmazeutische zusammensetzungen.
CA2098113A1 (en) Substances of polypeptide nature useful in human therapy
RU2398776C2 (ru) Тимус-специфический белок
Watanabe et al. The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7
DE4410136A1 (de) Tumorizide T-Lymphozyten
Rivera et al. The Chinchorro people of Northern Chile 5000 BC-500 BC, a review of their culture and relationships
DE60130634T2 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
EP0607593B1 (de) Verfahren zur Gewinnnung von Zellkulturen mit erhöhtem Gehalt an körpereigenen Zytokinen
AT400444B (de) Verfahren zur herstellung von oncostatin m